Internationale Pharmaceutica Sciencia

Available Online: https://ipharmsciencia.edwiserinternational.com

An Overview of Clinical Pharmacology of Delafloxacin

Rehman H, Naveed S*

Department of Pharmacy Practice, Faculty of Pharmacy, Jinnah University for Women, Pakistan

Article info

Received 29 December 2019
Revised 12 August 2020
Published 19 August 2020

*Corresponding author: Rehman H, Department of Pharmacy Practice, Faculty of Pharmacy, Jinnah University for Women, Pakistan; E-mail : drhinarehman@hotmail.com

Abstract

Objective: Delafloxacin is fluoroquinolone antibiotics indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI). It is new addition in the class of fluoroquinolone and shows better results with the pathogen Streptococcus pyogenes, Streptococcus agalactiae, Staphylococcus aureus and Methicillin with both susceptible and resistant conditions. By viewing, the current paper is based on clinical pharmacology and practice of Delafloxacin.

Methods: Phase I, II and III clinical trial has published on clinical efficacy and safety. Till phase III clinical trial, there is no significance safety concerns appeared. The article concludes the clinical pharmacology of Delafloxacin include basic mechanism of action, clinical pharmacology including pharmacokinetics and dynamics, clinical Efficacy and indicated the current therapeutic uses and practices.

Key Findings: No significant drug interaction has been reported yet and showed good tolerance in phase III clinical trial.

Conclusion: Delafloxacin can considered to be the best attractive option for gram positive and expect more usage with new practices and indications in future.

Keywords: *Delafloxacin; Pharmacokinetics; Pharmacology; Fluoroquinolone antibiotics*

Introduction

Delafloxacin chemically represents as "1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid". It includes in the classification of fluoroquinolone and presently in expansion by USA and was previously explored by Japan based Pharmaceutical Company. Chemically Delafloxacin differs from other members of the class fluoroquinolone in following three different ways: First, it does not have an emphatically essential gathering at the C-7 position, bringing about feeble causticity; Secondly the chlorine at C-8 (working together with the fluorine at the C-6 position) applies an unequivocally electron-pulling back impact on aromatic ring; and thirdly at N-1 there is a heteroaromatic substitution that adds to a very bigger sub-atomic surface than most fluoroquinolone [1-3].

Delafloxacin shows superior antibacterial action and having good in vitro power against Gram-positive creatures. This action is driven by the sub-atomic envelope and the polarity of the particle. Delafloxacin is dynamic against *Staphylococcus aureus*, including methicillin-safe strains (MRSA) (both quinolone susceptible and resistant) and against multidrug-safe isolates (Figure 1) [4-7].



Figure 1: Chemical structure of delafloxacin.

Clinical pharmacology of delafloxacin

The clinical pharmacology of Delafloxacin explained separately by pharmacokinetic and pharmacodynamics ways.

Pharmacokinetics

A Phase 1 clinical trial with single dose were designed for evaluating the efficacy of Delafloxacin under various conditions. In this phase 1 study 30 healthy human subjects were enrolled. As per the study design of the drug 3 arms were taken with the single dose of 900mg of Delafloxacin under fasting condition. In 1st arm of this study healthy subjects were fasting on 10 hours and dose of Delafloxacin were 900 mg, In second arm of the study, the subjects were advice to take high fat breakfast 30 minutes before dosing as per standardization of FDA however in third arm of the study fasting followed by high fat meal 2 hours after dosing. After the dosing parameters, drug was assessed on pharmacokinetics parameters in each group. Cmax on all three arms were 11.5, 9.14 and 11.8 mg/l and the time to reach Cmax were 1.25, 2.5 and 1.5 h while half-life time of Delafloxacin was 14.1, 12.9 and 12 h, respectively [8,9].

Delafloxacin antibacterial impact was further analysed with tigecycline on phase 2 clinical trial which were multicentre, randomize and double blind in skin and delicate tissue infections and also assessed in meta-analysis as well [10]. The sample size of the study were 150 patients. Two different doses with the route of IV were given with the strengths of 300 and 450 mg every 12 hour and compared with tigecycline with the route of intravenous in dosages of 100 mg in addition to IV 50 mg every 12 hour. The investigational study was performed for 5– 14 days in view of clinical result. No significant difference was found between the three treatment choices and each was effective in both *S. aureus* and MRSA skin and soft tissue diseases/infections. The ciprofloxacin MIC estimations of the pathogens went in the range of 0.12 and 32 mg/L, while for Delafloxacin it differed in the range of 0.004 and 0.12 mg/l [11,12].

Two Phase III trials are progressing or finished with Delafloxacin. They centre again around the treatment of intense bacterial skin and skin structure contaminations. The first thinks about Delafloxacin (300 mg intravenously) b.i.d. for up 5–14 days (ClinicalTrials.gov identifier: NCT01811732) and has been recently completed. The second one looks at Delafloxacin 300 mg intravenously b.i.d. for 3 days followed by 450 mg oral b.i.d. for up 5–14 days (ClinicalTrials.gov identifier: NCT01984684) to Vancomycin (15 mg/kg intravenously) + Aztreonam (2 g intravenously) b.i.d. Also, the US FDA has conceded Delafloxacin as a Qualified Infectious Disease Product for the signs of intense bacterial skin and skin structure contaminations (ABSSSI) and group obtained bacterial pneumonia (CABP) in October 2012. One may anticipate from these investigations to feature advantages of Delafloxacin in term of spectrum, permitting its utilization as a monotherapy and of oral bioavailability [13,14].

Delafloxacin is recently approved Fluoroquinolone (FQ), which has indicated great in vitro and in vivo action against significant pathogens related with group procured pneumonia (CAP) and intense bacterial skin and skin structure diseases (ABSSSI). It has been considered in the two diseases, however, is presently endorsed for ABSSSI. It additionally indicates great action against a wide range of microorganisms, including Gram-positive, Gram-negative, atypical, and anaerobic life forms. Delafloxacin is the main FQ with action against methicillin safe Staphylococcus aureus

(MRSA). It is accessible in oral and intravenous (IV) formulations [15-17].

Pharmacodynamics

Pharmacodynamics studies revealed that the fAUC/MIC proportion (where fAUC is the AUC for the free medication) is the primary driver of viability for fluoroquinolone [18]. Pharmacodynamics studies revealed that the fAUC/MIC proportion (where fAUC is the AUC for the free medication) is the primary driver of viability for fluoroquinolone. This likewise remains constant for Delafloxacin in animal data, the information acquired in a model of *S. aureus murine* thigh infection, which demonstrated that a 1 log decrease in inoculum can be reached for fAUC/MIC proportions ≤ 14.3 hour [19].

Early investigations including in-vitro pharmacodynamics models analysed Delafloxacin properties however fail to consider the conceivable part of protein official. They anticipated that Delafloxacin could accomplish higher bacterial executing against *S. aureus* and *S. pneumoniae* and have a lower affinity to choose for protection than levofloxacin at simulated regimens mimicking AUC achievable in humans [20,21] essentially because higher AUC/MIC ratios could be attained with Delafloxacin (12-times higher against *S. aureus* and 21–63-times higher for *S. pneumoniae* considering the particular strains utilized as a part of these investigational studies). Delafloxacin was likewise as viable as ciprofloxacin against *E. coli* at clinically-important recreated measurements (400 mg Delafloxacin versus 500 mg twice day by day ciprofloxacin, creating AUC/MIC proportions of 2200 and 1740 hour, respectively) yet required higher clinically related simulated dosages (400 mg twice day by day) to be at least effective as ciprofloxacin against *P. aeruginosa* (AUC/MIC proportions of 280 and 120 h for Delafloxacin and Ciprofloxacin, respectively) [22].

Clinical efficacy

The phase II clinical trial showed that the drug Delafloxacin is very well tolerated and have similar effectiveness as compared to other antibiotics like vancomycin, tigecycline and linezolid [1,23]. A posthoc investigation exhibited superior clinical achievement rates in obese patients with Delafloxacin contrasted with vancomycin in one Phase 2 clinical study with further moved towards phase III clinical trial with subjects having BMI 30 [15]. In phase 3 randomized, double blind, multicentre clinical trial with non-inferiority high risk and comparing the investigational drug with vancomycin plus aztreonam in the treatment of moderate to severe ABSSSI. These trials have currently published and fully analysed for quality [24].

Following are the Pooled Outcomes by Baseline Pathogens on modified intention to treat population (MITT population) [25]. In the following group, it has cleared that Delafloxacin has strong effects on Streptococcus agalactiae, Streptococcus pyogenes, Staphylococcus aureus with susceptible and resistant Methicillin (Table 1). Application of these type of study is low since rejection criteria was broad and included numerous comorbidities generally found in patients in danger for ABSSSI (hidden skin condition, debilitated blood vessel blood supply to furthest points, fringe neuropathy, liver infection, renal malady). More investigations are expected to sufficiently survey the place in treatment of Delafloxacin. There is as of now a continuous investigation contrasting Delafloxacin with Moxifloxacin in patients with group acquired pneumonia.

Table 1: Pooled Outcomes by Baseline Pathogens on modified intention to treat population (MITT population).

	Clinical Response at 48-72 hours(a)		**Investigator-Assessed Success at Follow-up (b)**	
Pathogen (%)	**Delafloxacin, n/N**	**Comparator, n/N (%)**	**Delafloxacin, n/N (%)**	**Comparator, n/N (%)**
Staphylococcus aureus Methicillin-susceptible Methicillin-resistant	271/319 (85.0%) 149/177 (84.2%) 125/144 (86.8%)	269/324 (83.0%) 148/180 (80.9%) 121/141 (85.8%)	275/319 (86.2%) 154/177 (87.0%) 122/144 (84.7%)	269/324 (83.0%) 153/183 (83.6%) 116/141 (82.3%)
Streptococcus pyogenes	17/23 (73.9%)	9/18 (50.0%)	21/23 (91.3%)	16/18 (88.9%)
Streptococcus agalactiae	10/14 (71.4%)	9/12 (75.0%)	12/14 (85.7%)	11/12 (91.7%)
Escherichia coli	12/14 (85.7%)	16/20 (80.0%)	12/14 (85.7%)	18/20 (90.0%)
Klebsiella pneumoniae	19/22 (86.4%)	22/23 (95.7%)	20/22 (90.9%)	21/23 (91.3%)

Pseudomonas aeruginosa	9/11 (81.8%)	11/12 (91.7%)	11/11 (100.0%)	12/12 (100.0%)

Dosing route

Delafloxacin is administer twice every day 300 mg intravenously and 450 mg orally. Hoover et al. assessed in phase I clinical trial with a few degrees of renal disappointment. The results about a proposal to diminish the Delafloxacin IV dosage to 200 mg b.i.d. for patients with extreme renal hindrance (eGFR 15–29 mL/min/1.73 m2). No dosage reduction has been recommended further for mild moderate and severe renal impairment.

Therapeutic uses

Delafloxacin is another age fluoroquinolone affirmed by FDA in 2017. It is particularly indicated for adults having bacterial skin and skin structure contaminations (ABSSSIs) caused by certain gram-positive and gram-negative pathogens, including methicillin-safe Staphylococcus aureus [26]. Delafloxacin is one of a kind with high anti- bacterial power increases as the pH of the local environmental condition increases and turns out to be more acidic, a normal for disease settings [4].

Delafloxacin has an excellent in-vitro activity against MRSA with the dosing range of 0.12 to 0.5 mg/ml [27]. It has established in comparative Phase II clinical trial that Delafloxacin has better cure statistically as compare to Linezolid and Vancomycin [1,6,7,27,28]. It has also established in Phase II clinical trial that Delafloxacin has better curing results on skin and skin structural infection as compare to tigecycline [1,11,13,23,29,30]. It has showed better tolerability and less severe side effects i.e. mild to moderate in gastrointestinal diseases. It has less potential on photo-toxicity and no effect on QT interval of heart and not produce any cardiac toxicity [23,24,29,31,32]. The disposition of delafloxacin after a single dose of 300-mg intravenous (IV) dose has been studied in a mass-balance study using adiolabeled delafloxacin in healthy male volunteers [19,33-40].

Clinical safety, tolerability, and toxicity

No significant safety concerns arise for 741 patients incorporated into the two Phase 3 trials. The common adverse effects were reported on clinical trials included sickness, looseness of the bowels, cerebral pain, transaminase elevation and swelling. There were no reports of tendinitis or ligament break, fringe neuropathy or myopathy; however, post marketing surveillance were very important to decide the danger related to Delafloxacin [11,15,41-44].

It has also established in comparative study with Delafloxacin, Linezolid and Vancomycin and results revealed that Delafloxacin has most repeating side effects and nausea were most common. The AST and ALT has been increasing in Vancomycin and Delafloxacin group however no response of hypoglycaemia was detected [23]. It showed good tolerance with 0.8% of withdrawals [17,45,46] and less adverse effects as compare to other groups [14,47]. In has also reported in clinical trial related to diarrhoea caused by Clostridium difficile with MICs (<0.015 µg/Ml) and having no side effects [27]. Globally, Phase I and II clinical trial showed the drug safe with no specific adverse events [32,33,48,49].

Drug-drug interaction

The drug does not demonstrate any clinically huge consequences for cytochrome P450 proteins and was not an inhibitor of any significant hepatic or renal medication transporter. The major route of administration is renal; around 40% of a Delafloxacin measurements is evidently cleared unaltered by the liver or conjugated as glucuronide metabolites by the liver [50].

A current report assessing the impacts of Delafloxacin on the pharmacokinetics of midazolam, a cytochrome P450 (CYP) 3A substrate, demonstrated that Delafloxacin did not find significant changes in midazolam pharmacokinetics [51].

Conclusion

Delafloxacin is the new addition in the class of fluoroquinolone and shows better results with the pathogen Streptococcus pyogenes, Streptococcus agalactiae, Staphylococcus aureus and Methicillin with both susceptible and resistant conditions. Clinical investigations have exhibited non-inferiority of delafloxacin contrasted with tigecycline, linezolid, vancomycin, and the mix of vancomycin in addition to aztreonam in the treatment of ABSSSI. No critical safety concerns have developed.

European patients hospitalized for the condition of MRSA cSSTI and could be authorised for early switch and discharge. This would result in significant reductions in hospitalization specifically for IV treatment and save €2000 per early discharge-eligible patient. In this view, Delafloxacin epitomises an electrifying opportunity. In conclusion it is surely be the promising option for the treatment but post marketing surveillance more strength the evidence.

References

1. Remy JM, Tow-Keogh CA, McConnell TS, et al. Activity of delafloxacin against methicillin-

resistant Staphylococcus aureus: Resistance selection and characterization. J Antimicr Chemo 2012; 67: 2814-2820.
2. de Souza Mendes CdU, de Souza Antunes AM. Pipeline of known chemical classes of antibiotics. Antibiotics 2013; 2: 500-534.
3. Bassetti M, Della Siega P, Pecori D, et al. Delafloxacin for the treatment of respiratory and skin infections. Expert Opinion Investigational Drugs 2015; 24: 433-442.
4. Lemaire S, Tulkens PM, Van Bambeke F. Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus. Antimicrobial Agents Chemotherapy 2011; 55: 649-658.
5. Lemaire S, Tulkens PM, Van Bambeke F. Contrasting effect of acidic pH on the extracellular and intracellular activities of delafloxacin (DFX) vs moxifloxacin (MXF) towards *S. aureus*. Antimicrobial Agents Chemotherapy 2010; 55: 649-658.
6. Almer LS, Hoffrage JB, Keller EL, et al. In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms. Antimicrobial Agents Chemotherapy 2004; 48: 2771-2777.
7. Harnett S, Fraise A, Andrews J, et al. Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492. J Antimicrobial Chemotherapy 2004; 53: 783-792.
8. Kocsis B, Szabo D. Delafloxacin: A novel fluoroquinolone introduced in clinical trials. Int J Clin Med Microbiol 2016; 2016.
9. Kocsis B, Domokos J, Szabo D. Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin. Annals Clin Microbiol Antimicrobials 2016; 15: 34.
10. Tasina E, Haidich AB, Kokkali S, et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: A meta-analysis. Lancet Infec Diseases 2011; 11: 834-844.
11. O'Riordan W, Mehra P, Manos P, et al. A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections. Int J Infec Diseases 2015; 30: 67-73.
12. Yahav D, Lador A, Paul M, et al. Efficacy and safety of tigecycline: A systematic review and meta-analysis. J Antimicrob Chemotherapy 2011; 66: 1963-1971.
13. Van Bambeke F. Delafloxacin, a non-zwitterionic fluoroquinolone in phase III of clinical development: Evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy. Future Microbiol 2015; 10:1111-1123.
14. Cammarata S, Gardovskis J, Farley B, et al., editors. Results of a global phase 3 study of delafloxacin (DLX) compared to vancomycin with aztreonam (VAN) in acute bacterial skin and skin structure infections (ABSSSI). Open Forum Infectious Diseases Oxford University Press 2015.
15. Herink M. Drug class update with new drug evaluation: Fluoroquinolones. 2012.
16. https://www.medscape.com/viewarticle/748570
17. Eure S. InPharmative Quarterly.
18. Calbo E, Garau J. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of community-acquired respiratory tract infections. Respiration 2005; 72: 561-571.
19. Burak E, Bortolon E, Molstad D, et al. Pharmacokinetics and pharmacodynamics of delafloxacin in *S. aureus murine* thigh infection models. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco 2009.
20. Firsov AA, Vostrov SN, Lubenko IY, et al. ABT492 and levofloxacin: Comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model. J Antimicrob Chemotherapy 2004; 54:178-186.
21. Firsov AA, Alferova IV, Smirnova MV, et al. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. Int J Antimicrob Agents 2005; 25:409-413.
22. Zinner SH, Vostrov SN, Alferova IV, et al. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model. Int J Antimicrobial Agents 2004; 24: 173-177.
23. Kingsley J, Mehra P, Lawrence LE, et al. A randomized, double-blind, phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin. J Antimicrobial Chemotherapy 2015; 71: 821-829.
24. Pullman J, Gardovskis J, Farley B, et al. Efficacy and safety of delafloxacin compared with

vancomycin plus aztreonam for acute bacterial skin and skin structure infections: A Phase 3, double-blind, randomized study. J Antimicrobial Chemotherapy 2017; 72: 3471-3480.
25. Chu Y, Qu J, Qu LY, et al. A meta-analysis of sequential intravenous/oral moxifloxacin monotherapy for treatment of skin and skin structure infections. Drug Res 2015; 65: 650-657.
26. Khan SA, Mazhar S, Shammas S, et al. Pharmacy Newsletter. 2017.
27. Nilius AM, Shen LL, Hensey-Rudloff D, et al. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrobial Agents Chemotherapy 2003; 47: 3260-3269.
28. Goldstein EJ, Citron DM, Merriam CV, et al. In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis. Antimicrobial Agents Chemotherapy 2003; 47: 3008-3011.
29. Litwin JS, Benedict MS, Thorn MD, et al. A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization. Antimicrobial Agents Chemotherapy 2015; 59: 3469-3473.
30. Lepak AJ, Andes DR. In vivo pharmacodynamic target assessment of delafloxacin against *Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae* in a murine lung infection model. Antimicrobial Agents Chemotherapy 2016; 60: 4764-4769.
31. Mogle BT, Steele JM, Thomas SJ, et al. Clinical review of delafloxacin: A novel anionic fluoroquinolone. J Antimicrob Chemotherapy 2018.
32. Cho JC, Crotty MP, White BP, et al. What is old is new again: Delafloxacin, a Modern fluoroquinolone: Pharmacotherapy. J Human Pharmacol Drug Therap 2018; 38: 108-121.
33. McEwen A, Lawrence L, Hoover R, et al. Disposition, metabolism and mass balance of delafloxacin in healthy human volunteers following intravenous administration. Xenobiotica 2015; 45: 1054-1062.
34. Lemaire S, Tulkens P, Bambeke F. Contrasting effects of acidic pH on the extracellular and intracellular activities of delafloxacin against Staphylococcus aureus. Antimicrob Agents Actions. 2011; 55: 649-658.
35. Hoover RK, Alcorn H, Lawrence L, et al. Delafloxacin pharmacokinetics in subjects with varying degrees of renal function. J Clin Pharmacol 2017; 10.
36. Dhangar KR, Shirkhedkar AA. Estimation of Delafloxacin using derivative spectrophotometry and area under curve in bulk material and in laboratory mixture. J Pharma Technol Res Management 2016; 4: 81-87.
37. Bassetti M, Pecori D, Cojutti P, et al. Clinical and pharmacokinetic drug evaluation of delafloxacin for the treatment of acute bacterial skin and skin structure infections. Expert Opinion Drug Metabol Toxicol 2017; 13: 1193-1200.
38. Rubino CM, Bhavnani SM, Burak E, et al. Pharmacokineticpharmacodynamic target attainment analyses supporting delafloxacin phase 3 dose regimen decisions. Fiftieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA 2010.
39. Longcor J, Hopkins S, Lawrence L, et al. Results of a phase 2 study of delafloxacin (DLX) compared to vancomycin (VAN) and linezolid (LNZ) in acute bacterial skin and skin structure infections (ABSSSI). Fifty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA; 2012.
40. Lawrence L, Longcor J, Li D, et al. Metabolism and mass balance of [14C]-delafloxacin in healthy human volunteers following intravenous administration. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA. 2012; 9-12.
41. Lawrence L, Benedict M, Hart J, et al. Pharmacokinetics (PK) and safety of single doses of delafloxacin administered intravenously in healthy human subjects. Fifty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA; 2011.
42. Lawrence L, Benedict M, Hart J, et al., editors. Pharmacokinetics (PK) and safety of single doses of delafloxacin administered intravenously in healthy human subjects, poster A2-045a. Abstr. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) American Society for Microbiology, Washington, DC; 2011.
43. Longcor J, Hopkins S, Wikler M, et al. A phase 2 study of the safety and efficacy of oral delafloxacin (DLX) in community acquired pneumonia (CAP). ID Week. 2012.
44. Thabit AK, Crandon JL, Nicolau DP. Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens. Int J Antimicrob Agents 2016; 48: 535-541.

45. Sain B, Sharma V, Sharma AK, et al. Dalafloxacin-Antibacterial: A review. Int J Res 2018; 6: 101.
46. Poulakou G, Giannitsioti E, Tsiodras S. What is new in the management of skin and soft tissue infections in 2016? Current Opinion Infectious Diseases 2017; 30: 158-171.
47. O'Riordan W, McManus A, Teras J, et al. A global phase 3 study of delafloxacin (DLX) compared to vancomycin/aztreonam (VAN/AZ) in patients with acute bacterial skin and skin structure infections (ABSSSI). Poster Presented at ID Week 2016.
48. Dumas J, Pucci MJ, Moeck G. Drug development for drug-resistant pathogens. Antimicrob Drug Resistance Springer 2017; 45-57.
49. Hoover R, Hunt T, Benedict M, et al. Single and multiple ascending-dose studies of oral delafloxacin: Effects of food, sex, and age. Clin Therap 2016; 38: 39-52.
50. Hoover R, Marbury TC, Preston RA, et al. Clinical pharmacology of delafloxacin in patients with hepatic impairment. J Clin Pharmacol 2017; 57: 328-335.
51. Paulson SK, Wood-Horrall RN, Hoover R, et al. The pharmacokinetics of the CYP3A substrate midazolam after steady-state dosing of delafloxacin. Clin Therap 2017; 39: 1182-1190.